ÂÜÀòÂÒÂ×

Derek LaPlaca is a Senior Scientist at Third Harmonic Bio since November 2023, focusing on selective KIT inhibitors for allergy and inflammation. Prior to this role, Derek served as Scientist II at Remix Therapeutics, developing small molecule degraders of MYB mRNA. At Syros Pharmaceuticals, Derek was Project Lead for the CDK11 program and Chemistry Lead for the CDK12 inhibitor program. Derek also contributed to significant projects at Intellia Therapeutics, where notable achievements included securing a $3 million grant from the Gates Foundation for lipid nanoparticle delivery and leading multiple CRISPR mRNA delivery projects. Early in the career, experience included research roles at Ra Pharmaceuticals, Worcester State University, and the University of Massachusetts Medical School. Derek holds a Bachelor of Science degree from Worcester State University.